Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger, D.B., Curran, P.J., Hruza, A., Voigt, J., Meng, Z., Mandal, A.K., Siddiqui, M.A., Basso, A.D., Gray, K.(2010) Bioorg Med Chem Lett 20: 5170-5174
- PubMed: 20674350 
- DOI: https://doi.org/10.1016/j.bmcl.2010.07.008
- Primary Citation of Related Structures:  
3NRM - PubMed Abstract: 
The synthesis and structure-activity relationships (SAR) of novel, potent imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors are described. The X-ray crystal structure of imidazo[1,2-a]pyrazine Aurora inhibitor 1j is disclosed. Compound 10i was identified as lead compound with a promising overall profile.
Organizational Affiliation: 
Department of Chemistry, Merck Research Laboratories, Cambridge, MA 02141, USA. david.belanger@merck.com